Indication

Cabotegravir long acting (CAB LA) injection is indicated, in combination with rilpivirine long acting (RPV LA) injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.

Medicine details

Medicine name:
cabotegravir (Vocabria)
SMC ID:
SMC2376
Pharmaceutical company
ViiV Healthcare
BNF chapter
Infections
Submission type
Full
Publication due date:
11 October 2021
SMC meeting date:
07 September 2021
Patient group submission deadline:
02 August 2021